文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

新型冠状病毒肺炎危重症患者插管时机与死亡率:单中心队列研究

Timing of Intubation and Mortality Among Critically Ill Coronavirus Disease 2019 Patients: A Single-Center Cohort Study.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在新冠肺炎危重症患者中,从ICU入住到插管的时间及插管前使用高流量鼻导管均与死亡率无关。

该回顾性队列研究纳入美国亚特兰大四所大学附属医院六个新冠肺炎专用ICU的231例成人患者,其中109例(47.2%)接受高流量鼻导管治疗,97例(42.0%)未经过高流量鼻导管直接插管。高流量鼻导管组中78例(71.6%)最终接受机械通气。共175例接受机械通气,按插管时间分为≤8小时(76例,43.4%)、8-24小时(57例,32.6%)和≥24小时(42例,24.0%)三组。结果显示插管时间与死亡率无关(≤8小时:38.2%;8-24小时:31.6%;≥24小时:38.1%;p=0.7),调整分析亦无关联。插管前使用高流量鼻导管与死亡率无关。作者认为新冠肺炎呼吸衰竭可与其他病因的低氧性呼吸衰竭类似管理。

要点

  • 在175例接受机械通气的新冠肺炎患者中,插管时间≤8小时、8-24小时、≥24小时三组死亡率分别为38.2%、31.6%、38.1%,差异无统计学意义(p=0.7)。
  • 调整分析未发现从ICU入住到插管的时间与死亡率之间存在关联。
  • 插管前使用高流量鼻导管与死亡率无关;高流量鼻导管组71.6%(78/109)最终接受机械通气。
  • 插管时间分组间初始静态顺应性、机械通气时长和ICU住院时间均无差异。
  • ≤8小时插管组更常见糖尿病、慢性合并症和更高的入ICU时SOFA评分。

适用人群与场景

  • 实验室确诊严重急性呼吸综合征冠状病毒2感染的成人患者,入住新冠肺炎专用ICU并接受高流量鼻导管或机械通气。
  • 研究场景为美国亚特兰大四所大学附属医院的六个新冠肺炎专用ICU。

研究设计与关键结果

  • 研究类型为回顾性队列研究,纳入231例入住ICU的新冠肺炎成人患者;109例(47.2%)接受高流量鼻导管治疗,97例(42.0%)未经过高流量鼻导管直接插管。
  • 高流量鼻导管组中78例(71.6%)最终接受机械通气;共175例接受机械通气,其中女性44.6%,黑人66.3%,中位年龄66岁(四分位距56-75岁)。
  • 175例机械通气患者中,76例(43.4%)在入ICU后8小时内插管,57例(32.6%)在8-24小时之间插管,42例(24.0%)在≥24小时后插管。
  • 死亡率按插管时间分组:≤8小时组38.2%,8-24小时组31.6%,≥24小时组38.1%,组间差异无统计学意义(p=0.7);调整分析未发现插管时间与死亡率的关联。
  • 插管时间分组间初始静态顺应性、机械通气时长和ICU住院时间无差异。
  • 插管前使用高流量鼻导管与死亡率无关。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,新冠肺炎呼吸衰竭可与其他病因的低氧性呼吸衰竭类似管理。
  • 本研究提示插管前使用高流量鼻导管与死亡率无关,从ICU入住到插管的时间与死亡率无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Increasing time to mechanical ventilation and high-flow nasal cannula use may be associated with mortality in coronavirus disease 2019. We examined the impact of time to intubation and use of high-flow nasal cannula on clinical outcomes in patients with coronavirus disease 2019.

DESIGN: Retrospective cohort study.

SETTING: Six coronavirus disease 2019-specific ICUs across four university-affiliated hospitals in Atlanta, Georgia.

PATIENTS: Adults with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection who received high-flow nasal cannula or mechanical ventilation.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Among 231 patients admitted to the ICU, 109 (47.2%) were treated with high-flow nasal cannula and 97 (42.0%) were intubated without preceding high-flow nasal cannula use. Of those managed with high-flow nasal cannula, 78 (71.6%) ultimately received mechanical ventilation. In total, 175 patients received mechanical ventilation; 44.6% were female, 66.3% were Black, and the median age was 66 years (interquartile range, 56-75 yr). Seventy-six patients (43.4%) were intubated within 8 hours of ICU admission, 57 (32.6%) between 8 and 24 hours of admission, and 42 (24.0%) greater than or equal to 24 hours after admission. Patients intubated within 8 hours were more likely to have diabetes, chronic comorbidities, and higher admission Sequential Organ Failure Assessment scores. Mortality did not differ by time to intubation (≤ 8 hr: 38.2%; 8-24 hr: 31.6%; ≥ 24 hr: 38.1%; p = 0.7), and there was no association between time to intubation and mortality in adjusted analysis. Similarly, there was no difference in initial static compliance, duration of mechanical ventilation, or ICU length of stay by timing of intubation. High-flow nasal cannula use prior to intubation was not associated with mortality.

CONCLUSIONS: In this cohort of critically ill patients with coronavirus disease 2019, neither time from ICU admission to intubation nor high-flow nasal cannula use were associated with increased mortality. This study provides evidence that coronavirus disease 2019 respiratory failure can be managed similarly to hypoxic respiratory failure of other etiologies.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hernandez-Romieu AC, Adelman MW, Hockstein MA, et al. Timing of Intubation and Mortality Among Critically Ill Coronavirus Disease 2019 Patients: A Single-Center Cohort Study. Crit Care Med. 2020. PMID: 32804790. doi:10.1097/CCM.0000000000004600

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。